Chattopadhyay A, Rathinam SR, Gonzales JA, Kelly NK, Thundikandy R, Kanakath A, S Murugan B, Vedhanayaki R, Lim LL, Suhler EB et al..  2023.  Association between Quality of Life and Visual Acuity in a Randomized Clinical Trial of Patients with Uveitis Taking Antimetabolites.. Ocul Immunol Inflamm. :1-9.

Sura AA, Sun Y, Reddy AK, Rathinam SR, Gonzales JA, Thundikandy R, Vedhanayaki R, Kanakath A, Murugan B, Doan TA et al..  2023.  Reduced Dose Methotrexate and Mycophenolate Mofetil in Noninfectious Uveitis: A Sub-Analysis from the First-Line Antimetabolites as Steroid Sparing Therapy (FAST) Trial.. Ocul Immunol Inflamm. :1-6.

Reddy AK, D Miller C, Sura AA, Rathinam SR, Gonzales JA, Thundikandy R, Kanakath A, Murugan B, Vedhanayaki R, Lim LL et al..  2023.  Risk of failing both methotrexate and mycophenolate mofetil from the First-line Antimetabolites as Steroid-sparing Treatment (FAST) uveitis trial.. J Ophthalmic Inflamm Infect. 13(1):29.

Bui AD, Kong CL, Kelly NK, Rathinam SR, Gonzales JA, Thundikandy R, Kanakath A, Murugan B, Vedhanayaki R, Lim LL et al..  2022.  Time to Uveitis Control with Methotrexate and Mycophenolate Mofetil.. Ophthalmology. 

Rathinam SR, Gonzales JA, Thundikandy R, Kanakath A, S Murugan B, Vedhanayaki R, Lim LL, Suhler EB, Al-Dhibi HA, Doan T et al..  2019.  Effect of Corticosteroid-Sparing Treatment With Mycophenolate Mofetil vs Methotrexate on Inflammation in Patients With Uveitis: A Randomized Clinical Trial.. JAMA. 322(10):936-945.